|
Orthologous residues
|
|
PARK2 (human): Y143‑p, PARK2 (mouse): Y142‑p
|
|
Characterization
|
|
Methods used to characterize site in vivo:
mass spectrometry (in vitro), phospho-antibody, western blotting
|
|
Disease tissue studied:
neuroblastoma, Parkinson's disease
|
|
Relevant cell lines - cell types - tissues:
'neuron, striatal'-brain, 'neuron, substantia nigra'-brain, SH-SY5Y (neural crest)
|
|
Cellular systems studied:
cell lines, tissue
|
|
Species studied:
human
|
|
Enzymes shown to modify site in vitro:
|
|
|
|
Upstream Regulation
|
|
Potential in vivo enzymes for site:
|
|
Type
|
Enzyme
|
Evidence
|
Notes
|
|
KINASE
|
Abl (human)
|
siRNA inhibition of enzyme, co-immunoprecipitation, transfection of inactive enzyme, transfection of wild-type enzyme, pharmacological activator of upstream enzyme, pharmacological inhibitor of upstream enzyme
|
|
|
|
Treatments, proteins and their effect on site modification:
|
|
Treatments
|
Referenced Treatments
|
Manipulated Protein
|
Referenced Protein
|
Effect
|
Notes
|
|
MPP+
|
|
|
|
increase
|
|
|
STI571
|
MPP+
|
|
|
inhibit treatment-induced increase
|
|
|
DA
|
|
|
|
increase
|
|
|
STI571
|
DA
|
|
|
inhibit treatment-induced increase
|
|
|
siRNA
|
MPP+
|
|
|
inhibit treatment-induced increase
|
siRNA Abl
|
|
|
Downstream Regulation
|
|
Effect of modification (function):
enzymatic activity, inhibited, ubiquitination
|
|
Comments:
inhibits PARK2 autoubiquitination
|
|
Associated Diseases
|
|
Diseases:
|
Alterations:
|
Comments:
|
|
Parkinson's disease
|
increased
|
|
|
